India MCA Insolvency Liquidation Filings — September 22, 2026

Resolution plan implementation is progressing; new board of 5 directors appointed, including Sridhar Muppidi as CMD, signaling a fresh start and potential for operational turnaround. The merger of PurpleTalk India into Baron Infotech is a key catalyst for value creation.

NCLT dispensation of shareholder/creditor meetings for the demerger streamlines the approval process, removing a major execution hurdle. The demerger of the asset-light business with an appointed date of Jan 1, 2026, is a step closer to unlocking value from the managed workspace segment.

CoC's approval to file applications under Sections 43 and 66 of the IBC indicates a proactive stance to claw back preferential or undervalued transactions. This could lead to increased asset recoveries for creditors, potentially improving the final resolution value.

The CoC's approval of CIRP costs and IRP remuneration, despite deferring valuers, shows a controlled process. However, the deferral of key appointments could delay the resolution process, creating a holding pattern.

The 11th CoC meeting with a 90-day extension request indicates the CIRP is dragging on, now 11 months from initiation (Oct 2025). This prolonged timeline increases the risk of value erosion and lowers the likelihood of a favorable resolution for creditors.

The approval of Rs 23.1 lakh in CIRP expenses, while small, adds to the total insolvency cost. The company remains in distress with no financial turnaround, indicating a prolonged and costly resolution process.

CIRP timeline extended by 90 days, now exceeding 11 months. Prolonged insolvency increases legal and administrative costs, and the delay in selecting a resolution plan raises the risk of liquidation.

Deferral of registered valuers and transaction auditor appointments to the next CoC meeting creates uncertainty and delays the resolution process, potentially impacting the timeline for submitting a resolution plan.

The company remains under CIRP with no financial turnaround. The pursuit of avoidance claims (Sections 43/66) could lead to lengthy litigation, further delaying resolution and increasing costs.

All new director appointments are subject to shareholder approval, which introduces execution risk. Any delay or rejection by shareholders could stall the implementation of the resolution plan.

The demerger scheme remains subject to other regulatory approvals. Any delay or rejection by other regulators could derail the restructuring, leaving the company in a state of uncertainty.

The lack of financial disclosures in 5/6 filings (no revenue, margins, or debt figures) makes it difficult to assess the fundamental health of these companies, increasing investment risk.

The NCLT order in I.A. (IBC) No. 549/KB/2026, noted in the meeting, could involve legal challenges or specific directives that may impact the CIRP's direction, adding to the uncertainty.

The merger of PurpleTalk India and the appointment of a new board present a clean-slate opportunity. Investors should monitor the implementation of the resolution plan for potential value creation as the company restructures its operations.

The demerger of the asset-light business is a clear catalyst. The streamlined approval process (dispensation of meetings) increases the likelihood of completing the demerger, which could unlock value for shareholders of the resulting entity.

The CoC's action under Sections 43/66 could lead to the recovery of assets that were transferred out of the company before CIRP. This potential increase in the asset base could improve the recovery for creditors and potentially offer a better resolution plan.

The deferral of valuers and transaction auditor appointments suggests the CoC is being meticulous. The next CoC meeting could bring clarity on the resolution process, and the appointment of a transaction auditor could uncover hidden value.

The 90-day extension, while a risk, also provides a window for the RP to evaluate all resolution plans thoroughly. A well-negotiated resolution plan could still offer a better outcome for creditors than a quick but undervalued sale.

The active use of IBC provisions (Sections 43/66) by creditors across filings signals a trend towards maximizing recoveries. This could lead to higher recovery rates in the long run, making distressed debt investing more attractive.

2/6 filings (Radhagobind, Astron) show CIRPs extending beyond 12 months, with Radhagobind seeking a 90-day extension. This indicates systemic delays in the resolution process, increasing costs and reducing asset values.

1/6 filings (Astron Paper) shows CoC approving actions under Sections 43/66 of the IBC. This suggests a growing trend of creditors pursuing avoidance claims to expand the asset pool, which could become a standard practice in Indian insolvencies.

1/6 filings (Baron Infotech) shows a company transitioning to a new board and implementing a merger, indicating a shift from resolution to value creation. This phase presents opportunities for investors to back new management teams.

5/6 filings lack any financial metrics (revenue, margins, debt). This is a major challenge for investors, as it prevents fundamental analysis and forces reliance on process-driven signals, increasing the risk of mispricing.

1/6 filings (EFC I) shows NCLT dispensing with meetings for a demerger, indicating a more efficient approval process for schemes of arrangement. This could encourage more companies to use demergers as a restructuring tool.

Monitor the outcome of the 90-day extension request and the NCLT order in I.A. (IBC) No. 549/KB/2026. The next CoC meeting will be critical to see if a resolution plan is selected. [Date: Next CoC meeting TBD]

Watch for the next CoC meeting to see if the appointment of registered valuers and transaction auditor is approved. A delay could signal deeper issues in the resolution process. [Date: Next CoC meeting TBD]

Monitor the shareholder approval for the new board of directors and the progress of the PurpleTalk India merger. Any delay could impact the implementation timeline. [Date: Shareholder meeting TBD]

Track the progress of the demerger scheme through other regulatory approvals. The appointed date of Jan 1, 2026, is a key milestone to watch. [Date: Appointed Date Jan 1, 2026]

Watch for the outcome of the application under Sections 43/66 and any subsequent legal proceedings. The recovery of assets could significantly alter the company's valuation. [Date: NCLT hearing TBD]

Monitor the NCLT's stance on the extension requests and avoidance applications. A more stringent approach could accelerate resolutions, while a lenient one could prolong the process. [Date: Ongoing]